Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Hansoh Pharmaceutical Group Company Limited has entered into an exclusive licensing agreement with Guangzhou Lupeng Pharmaceutical Co., Ltd. to develop and commercialize the drug LP-168 in China. The agreement includes milestones and royalty payments that could total up to RMB729 million. LP-168, currently in Phase II clinical trials, is a promising treatment for non-tumor indications and is part of Hansoh’s strategic growth in the pharmaceutical industry.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.